Search results for "ORIGINAL REPORTS"

showing 10 items of 15 documents

Patients With Cancer and COVID-19: A WhatsApp Messenger-Based Survey of Patients' Queries, Needs, Fears, and Actions Taken

2020

PURPOSE This descriptive investigation was undertaken at three oncology units to report queries, needs, and fears related to severe acute respiratory syndrome coronavirus 2 (COVID-19) of patients with cancer and to avoid uncontrolled treatment delays or withdrawal, behavioral mistakes, and panic. PATIENTS AND METHODS All queries spontaneously delivered through the WhatsApp instant messaging system commonly used by patients to communicate with oncology units were collected and grouped by homology in five categories. Responses to the queries were given according to recommendations by the Italian Association of Medical Oncology through WhatsApp and by subsequent phone calls. Patients were also…

0301 basic medicineCancer Research2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)WhatsApp messenger cancer patient reactions action taken COVID-19 outbreak sentimental analysisPneumonia ViralMEDLINETime to treatmentTime-to-Treatment03 medical and health sciences0302 clinical medicineNeoplasmsSurveys and QuestionnairesOriginal ReportsPandemicmedicineHumansIntensive care medicinePandemicsText Messagingbusiness.industryCOVID-19CancerFearmedicine.diseasePneumonia030104 developmental biologyOncology030220 oncology & carcinogenesisCoronavirus Infectionsbusiness
researchProduct

Outcomes of BRAF V600E Pediatric Gliomas Treated With Targeted BRAF Inhibition.

2020

PURPOSE Children with pediatric gliomas harboring a BRAF V600E mutation have poor outcomes with current chemoradiotherapy strategies. Our aim was to study the role of targeted BRAF inhibition in these tumors. PATIENTS AND METHODS We collected clinical, imaging, molecular, and outcome information from patients with BRAF V600E–mutated glioma treated with BRAF inhibition across 29 centers from multiple countries. RESULTS Sixty-seven patients were treated with BRAF inhibition (pediatric low-grade gliomas [PLGGs], n = 56; pediatric high-grade gliomas [PHGGs], n = 11) for up to 5.6 years. Objective responses were observed in 80% of PLGGs, compared with 28% observed with conventional chemotherapy …

0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyHematologyendocrine system diseasesbusiness.industrydigestive system diseases3. Good healthBRAF V600E03 medical and health sciencesenzymes and coenzymes (carbohydrates)030104 developmental biology0302 clinical medicineOncology030220 oncology & carcinogenesisInternal medicineMutation (genetic algorithm)Original Reportsmedicinebusinessskin and connective tissue diseasesneoplasmsChemoradiotherapyJCO precision oncology
researchProduct

Twelve-Month Estrogen Levels in Premenopausal Women With Hormone Receptor–Positive Breast Cancer Receiving Adjuvant Triptorelin Plus Exemestane or Ta…

2016

Purpose To describe estradiol (E2), estrone (E1), and estrone sulfate (E1S) levels during the first year of monthly triptorelin plus exemestane or tamoxifen and to assess possible suboptimal suppression while receiving exemestane plus triptorelin. Patients and Methods Premenopausal patients with early breast cancer on the Suppression of Ovarian Function Trial who selected triptorelin as the ovarian suppression method and were randomly assigned to exemestane plus triptorelin or tamoxifen plus triptorelin were enrolled until the target population of 120 patients was reached. Blood sampling time points were 0, 3, 6, 12, 18, 24, 36, and 48 months. Serum estrogens were measured with a highly sen…

Adult0301 basic medicineOncologyCancer Researchmedicine.medical_specialtyAntineoplastic Agents HormonalEstronemedicine.drug_classBreast NeoplasmsEstrone03 medical and health scienceschemistry.chemical_compoundFollicle-stimulating hormone0302 clinical medicineBreast cancerExemestaneInternal medicineAntineoplastic Combined Chemotherapy ProtocolsmedicineHumansGynecologyTriptorelin PamoateEstradiolbusiness.industryOvaryEstrogensORIGINAL REPORTSLuteinizing Hormonemedicine.diseaseTriptorelinAndrostadienesTamoxifen030104 developmental biologyOncologychemistryChemotherapy AdjuvantEstrogen030220 oncology & carcinogenesisFemaleFollicle Stimulating HormonebusinessTamoxifenmedicine.drugBlood samplingJournal of Clinical Oncology
researchProduct

Hematopoietic stem-cell transplantation for advanced systemic mastocytosis

2014

Purpose Advanced systemic mastocytosis (SM), a fatal hematopoietic malignancy characterized by drug resistance, has no standard therapy. The effectiveness of allogeneic hematopoietic stem-cell transplantation (alloHCT) in SM remains unknown. Patients and Methods In a global effort to define the value of HCT in SM, 57 patients with the following subtypes of SM were evaluated: SM associated with clonal hematologic non–mast cell disorders (SM-AHNMD; n = 38), mast cell leukemia (MCL; n = 12), and aggressive SM (ASM; n = 7). Median age of patients was 46 years (range, 11 to 67 years). Donors were HLA-identical (n = 34), unrelated (n = 17), umbilical cord blood (n = 2), HLA-haploidentical (n = 1)…

AdultMaleCancer Researchmedicine.medical_specialtyTransplantation ConditioningAdolescentmedicine.medical_treatmentMedizinDrug resistanceHematopoietic stem cell transplantationMastocytosis SystemicInternal medicinemedicineHumansTransplantation HomologousSystemic mastocytosisChildSurvival rateAgedRetrospective StudiesmastocytosisHematologybusiness.industryRemission InductionHematopoietic Stem Cell TransplantationORIGINAL REPORTSMiddle Agedmedicine.diseaseMast cell leukemia3. Good healthSurvival RateTransplantationSettore MED/15 - MALATTIE DEL SANGUEHaematopoiesisTreatment OutcomeOncologyImmunologyCancer researchFemalebusinesstransplantation
researchProduct

Belinostat in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma: Results of the Pivotal Phase II BELIEF (CLN-19) Study

2015

Purpose Peripheral T-cell lymphomas (PTCLs) represent a diverse group of non-Hodgkin lymphomas with a poor prognosis and no accepted standard of care for patients with relapsed or refractory disease. This study evaluated the efficacy and tolerability of belinostat, a novel histone deacetylase inhibitor, as a single agent in relapsed or refractory PTCL. Patients and Methods Patients with confirmed PTCL who experienced progression after ≥ one prior therapy received belinostat 1,000 mg/m2 as daily 30-minute infusions on days 1 to 5 every 21 days. Central assessment of response used International Working Group criteria. Primary end point was overall response rate. Secondary end points included …

AdultMaleOncologyCancer Researchmedicine.medical_specialtymedicine.drug_classAntineoplastic AgentsKaplan-Meier EstimateHydroxamic AcidsDisease-Free SurvivalDrug Administration Schedulechemistry.chemical_compoundRefractoryInternal medicineClinical endpointHumansMedicineInfusions IntravenousAgedAged 80 and overSulfonamidesbusiness.industryHistone deacetylase inhibitorLymphoma T-Cell PeripheralORIGINAL REPORTSMiddle Agedmedicine.diseaseLymphomaSurgeryHistone Deacetylase InhibitorsClinical trialTreatment OutcomePrior TherapyOncologyTolerabilitychemistryDrug Resistance NeoplasmFemaleNeoplasm Recurrence LocalbusinessBelinostatJournal of Clinical Oncology
researchProduct

Deletion of the PER3 Gene on Chromosome 1p36 in Recurrent ER-Positive Breast Cancer

2010

El pdf del artículo es la versión de autor.-- et al.

Cancer ResearchMicroarrayGene DosageGene ExpressionEstrogen receptorBreast NeoplasmsGene dosageMiceBreast cancerOriginal ReportsAnimalsHumansMedicineGenetic Predisposition to DiseaseCopy-number variationskin and connective tissue diseasesSequence Deletionbusiness.industryCancerPeriod Circadian ProteinsPrognosismedicine.diseaseSurvival AnalysisDisease Models AnimalReceptors EstrogenOncologyChromosomes Human Pair 1Cancer researchFemaleBreast diseaseNeoplasm Recurrence LocalbusinessTamoxifenmedicine.drugJournal of Clinical Oncology
researchProduct

Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe

2020

Purpose Oncofertility focuses on providing fertility and endocrine-sparing options to patients who undergo life-preserving but gonadotoxic cancer treatment. The resources needed to meet patient demand often are fragmented along disciplinary lines. We quantify assets and gaps in oncofertility care on a global scale. Methods Survey-based questionnaires were provided to 191 members of the Oncofertility Consortium Global Partners Network, a National Institutes of Health–funded organization. Responses were analyzed to measure trends and regional subtleties about patient oncofertility experiences and to analyze barriers to care at sites that provide oncofertility services. Results Sixty-three res…

Cancer Researchmedicine.medical_specialtyReferralmedia_common.quotation_subjectBest practiceMEDLINEFertilitylcsh:RC254-282Cost EffectivenessFertilidade03 medical and health sciences0302 clinical medicineSupportive Care and Quality of LifeJournal ArticleQuality of CareMedicineFertility preservationmedia_commonOncofertilityEthicsMedicine(all)Response rate (survey)030219 obstetrics & reproductive medicinebusiness.industryHealth Services and OutcomesORIGINAL REPORTSlcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensSupportive CarePolicy AnalysisWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]3. Good healthFertilityOncology030220 oncology & carcinogenesisFamily medicineScale (social sciences)Quality of Life/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428business
researchProduct

Survey of third-party parenting options associated with fertility preservation available to patients with cancer around the globe

2018

Purpose In the accompanying article, “Survey of Fertility Preservation Options Available to Patients With Cancer Around the Globe,” we showed that specific fertility preservation services may not be offered at various sites around the world because of cultural and legal barriers. We assessed global and regional experiences as well as the legal status of third-party reproduction and adoption to serve as a comprehensive international data set and resource for groups that wish to begin oncofertility interventions. Methods We provide data on the legalities of third-party assisted reproductive technologies and other family-building options in the 28 oncofertility-practicing countries surveyed. R…

Cancer Researchmedicine.medical_specialtyResource (biology)fertility preservationPsychological interventionMEDLINEGlobeReproductive technologylcsh:RC254-28203 medical and health sciences0302 clinical medicineSupportive Care and Quality of LifeNeoplasmsSurveys and QuestionnairesOriginal ReportsJournal ArticlemedicineGlobal healthHumansFertility preservationReferral and ConsultationCancerOncofertility030219 obstetrics & reproductive medicineParentingbusiness.industryHealth Services and OutcomesPublic relationslcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensWomen's cancers Radboud Institute for Health Sciences [Radboudumc 17]3. Good healthSurgerymedicine.anatomical_structureOncology030220 oncology & carcinogenesis/dk/atira/pure/researchoutput/pubmedpublicationtype/D016428businessreproductive medicine
researchProduct

Cervical Cancer-Associated Suffering: Estimating the Palliative Care Needs of a Highly Vulnerable Population

2021

PURPOSE To enable design of optimum palliative care for women with cervical cancer, we studied the most common types of suffering and their severity, prevalence, and duration. METHODS We first reviewed the literature on the major types, severity, prevalence, and duration of suffering associated with cervical cancer. We then conducted a modified Delphi process with experts in cervical cancer care to supplement the literature. For each type of suffering, we distinguished between decedents (those who die from cervical cancer in a given year) and nondecedents (those who have cervical cancer in a given year but do not die). By applying the suffering prevalence and duration estimates to the numbe…

Cervical cancerGynecologic CancerCancer Researchmedicine.medical_specialtyPalliative carebusiness.industryMEDLINEORIGINAL REPORTSmedicine.disease03 medical and health sciences0302 clinical medicineOncology030220 oncology & carcinogenesismedicineVulnerable population030212 general & internal medicineIntensive care medicinebusinessJCO Global Oncology
researchProduct

Elective Cancer Surgery in COVID-19-Free Surgical Pathways during the SARS-CoV-2 Pandemic: An International, Multicenter, Comparative Cohort Study

2020

PURPOSE As cancer surgery restarts after the first COVID-19 wave, health care providers urgently require data to determine where elective surgery is best performed. This study aimed to determine whether COVID-19–free surgical pathways were associated with lower postoperative pulmonary complication rates compared with hospitals with no defined pathway. PATIENTS AND METHODS This international, multicenter cohort study included patients who underwent elective surgery for 10 solid cancer types without preoperative suspicion of SARS-CoV-2. Participating hospitals included patients from local emergence of SARS-CoV-2 until April 19, 2020. At the time of surgery, hospitals were defined as having a …

MaleCancer ResearchOutcome AssessmentInternational CooperationSettore MED/18 - CHIRURGIA GENERALESettore MED/19 - Chirurgia Plastica030230 surgeryAged; Aged 80 and over; COVID-19; Cohort Studies; Critical Care; Elective Surgical Procedures; Epidemics; Female; Humans; International Cooperation; Logistic Models; Male; Middle Aged; Neoplasms; Outcome Assessment Health Care; Postoperative Complications; SARS-CoV-2Cohort Studies0302 clinical medicineOperating theaterPostoperative Complicationscohort studiesNeoplasmsHealth caremiddle agedOutcome Assessment Health Care80 and overMedicineLungCancerCOVID-19/epidemiologyAged 80 and overOUTCOMESManchester Cancer Research CentrePulmonary ComplicationORIGINAL REPORTSMiddle AgedagedOncologyElective Surgical Procedures030220 oncology & carcinogenesisPneumonia & InfluenzaFemalePatient SafetyElective Surgical ProcedureLife Sciences & Biomedicine6.4 SurgeryCohort studyHumanmedicine.medical_specialtyelective surgical procedures/methodsLogistic ModelCritical CareAged; Aged; 80 and over; COVID-19; Cohort Studies; Critical Care; Elective Surgical Procedures; Epidemics; Female; Humans; International Cooperation; Logistic Models; Male; Middle Aged; Neoplasms; Outcome Assessment; Health Care; Postoperative Complications; SARS-CoV-2Clinical SciencesOncology and CarcinogenesisEpidemic[SDV.CAN]Life Sciences [q-bio]/Cancer-.cancer surgery ; COVID-19 ; SARS-CoV-2 pandemicepidemicsCOVIDSurg CollaborativeNOoutcome assessment health care/methods03 medical and health sciencesmaleSettore MED/28 - Malattie OdontostomatologicheClinical ResearchHumans1112 Oncology and CarcinogenesisOncology & CarcinogenesisElective surgeryEpidemicsElective Cancer Surgery in SARS-CoV-2 Elective Cancer Surgery in COVID-19 covid 19 sars-cov-2AgedScience & TechnologyElective Surgical Procedurebusiness.industrySARS-CoV-2PreventionResearchInstitutes_Networks_Beacons/mcrcEvaluation of treatments and therapeutic interventionsCOVID-191103 Clinical SciencesPneumoniaOdds ratiomedicine.diseaseHealth CarePneumoniaGood Health and Well Beingneoplasms/surgeryLogistic Modelscritical care/methodsEmergency medicinepostoperative complications/prevention & controlNeoplasmPostoperative ComplicationCohort Studiebusinessaged 80 and overSARS-CoV-2/physiologylogistic models
researchProduct